Loading
IARC estimates 8,815 new cancer cases and 3,814 cancer deaths in United Arab Emirates in 2024; the commonest new cancers are breast, colorectum and thyroid. This page is assembled automatically from OnCo's data: 10 trials with a site there, 2 institutions and 3 people, and says what OnCo does not yet hold.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Breast | 1,774 | 59.2 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Colorectum | 1,005 | 18.4 | Colorectal cancer |
| Thyroid | 682 | 6.6 | Thyroid cancer |
| Prostate | 595 | 25.0 | Prostate cancer |
| Trachea, bronchus and lung | 449 | 10.2 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Leukaemia | 423 | 6.3 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Bladder | 380 | 8.9 | Bladder & urothelial cancer |
| Non-Hodgkin lymphoma | 368 | 6.0 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Corpus uteri | 250 | 11.5 | Endometrial cancer |
| Stomach | 239 | 4.6 | Gastric & gastro-oesophageal junction cancer |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Breast | 482 | 17.5 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Colorectum | 444 | 8.3 | Colorectal cancer |
| Trachea, bronchus and lung | 378 | 8.6 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Leukaemia | 263 | 4.1 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Pancreas | 190 | 4.0 | Pancreatic ductal adenocarcinoma |
| Stomach | 174 | 3.6 | Gastric & gastro-oesophageal junction cancer |
| Liver and intrahepatic bile ducts | 173 | 4.0 | Hepatocellular carcinoma |
| Non-Hodgkin lymphoma | 153 | 2.6 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Prostate | 150 | 6.3 | Prostate cancer |
| Bladder | 146 | 3.6 | Bladder & urothelial cancer |
| Trial | Lead sponsor | ||||
|---|---|---|---|---|---|
| Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 216 | 2026-10-06 | |
| Phase 3 | Recruiting | AstraZeneca | 89 | 2026-09-08 | |
IZABRIGHT-Breast01 NCT06926868 | Phase 2/3 | Recruiting | Bristol-Myers Squibb | 295 | 2026-08-10 |
| Phase 1/2 | Recruiting | Ellipses Pharma | 52 | 2026-07-01 | |
| Phase 3 | Recruiting | GlaxoSmithKline | 277 | 2026-05-26 | |
| Phase 3 | Recruiting | Celgene | 160 | 2026-05-20 | |
| Phase 3 | Active not recruiting | Hoffmann-La Roche | 198 | 2026-10-02 | |
| Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 119 | 2026-08-26 | |
CAMBRIA-1 & CAMBRIA-2 NCT05952557 | Phase 3 | Active not recruiting | AstraZeneca | 661 | 2026-08-10 |
| Phase 2 | Active not recruiting | GlaxoSmithKline | 99 | 2026-06-15 |
Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in United Arab Emirates, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in United Arab Emirates is open is on the registry page, under Contacts and Locations.
People whose main affiliation in OnCo is an institution or company in United Arab Emirates.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. United Arab Emirates is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
United Arab Emirates is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.